By Judy Garber, MD, MPH We know that women who inherit harmful mutations in the genes BRCA1 or BRCA2 have a sharply increased risk of developing breast and/or ovarian cancer at an early age (prior to menopause). In fact, women with inherited BRCA1 or 2 mutations are about five times more likely to develop breast cancer – and at least 10 times more likely to develop ovarian cancer – than women without such mutations, according to the National Cancer Institute.
Pink may be the color for breast cancer advocacy, but that doesn’t mean men can’t be diagnosed with the disease. Each year, 2,000 men in the U.S. receive a breast cancer diagnosis. Current treatments are highly effective in men whose cancer is treated early. However, because men aren’t familiar with breast cancer symptoms, diagnosis is often delayed.
Win or lose, Miss America contestant Allyn Rose made news with her decision to undergo a double mastectomy. According to the Associated Press, Rose, who lost her mother to breast cancer, inherited a rare genetic mutation which might put her at greater risk for developing cancer. Her decision to have the preventive surgery has sparked questions about genetics, cancer risk and strategies for preventing cancer. If you have a question about genetic factors that increase cancer risk, you can ask the Dana-Farber cancer genetics team.
When Jane Davis was diagnosed with breast cancer last July, she began learning as much as she could about her disease. Davis quickly discovered one of the most startling statistics about breast cancer: Up to 40 percent of women who have a lumpectomy require a second surgery. That’s because surgeons often cannot microscopically remove the entire tumor. But Mehra Golshan, MD, FACS, director of Breast Surgical Services at Dana-Farber/Brigham and Women’s Cancer Center, is trying to change that with a phase I breast surgery pilot study. It’s the first of its kind in the world.
by Laura Dominici, MD Mammograms are the most effective tool for screening women for breast cancer. But mammography isn’t perfect: it may be slightly less effective for women with dense breasts. About half of all women have fairly dense breasts, which contain relatively large amounts of fibrous and glandular tissue and less fat. (Fibrous tissue supports and gives shape to the breast; glandular tissue produces and transports milk.) Breast density, which tends to be high in young women, often declines with age. On a mammogram, dense breast tissue appears as light gray or white, the same shades that can indicate …
by Erica Mayer, MD, MPH In 1974, when First Lady Betty Ford announced that she had undergone a mastectomy for breast cancer, it was a turning point in people’s willingness to talk about the disease. Prior to that, discussing cancer of any type, even with one’s family or friends, was often taboo. The First Lady’s openness about her cancer helped create a space in which women felt more comfortable talking about their experience – and about being screened for the disease.
Aromatase inhibitors (AIs), such as Arimidex, Aromasin, and Femara, have proven to be more effective than previous hormonal treatments for treating both early and advanced breast cancer in post-menopausal women whose tumors are dependent on estrogen. Compared with tamoxifen, these drugs are less likely to cause blood clots or raise the risk of endometrial cancer. As a result, AIs are used both in patients with early breast cancer and in those with metastatic disease.
It was glitter and glue when patients, visitors, and Dana-Farber staff gathered on Oct. 4 to create art on an unusual canvas – bras. Hosted by Friends’ Place and Dana-Farber’s Creative Arts Program, the “Decorate a Brassiere” art therapy event allowed attendees to creatively honor Breast Cancer Awareness Month.